SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sonpavde G, Sternberg CN. Contemporary management of metastatic castration-resistant prostate cancer. Curr Opin Urol 2011; 21: 2417
  • 2
    Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10: 58093
  • 3
    Higano CS, Small EJ, Schellhammer P et al. Sipuleucel-T. Nat Rev Drug Discov 2010; 9: 5134
  • 4
    Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncologist 2006; 11: 45162
  • 5
    Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 41122
  • 6
    Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 36709
  • 7
    Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010; 363: 47981
  • 8
    Chambers JD, Neumann PJ. Listening to Provenge – what a costly cancer treatment says about future medicare policy. N Engl J Med 2011; 364: 16879
  • 9
    Provenge – FDA full prescribing information. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf. Accessed 10 November 2011
  • 10
    Petrylak DP, Dawson NA, Gardner T et al. Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol 2010; 28 (Suppl.): 15s (abstr 4551)
  • 11
    Sims RB, Lin L, dela Rosa CP et al. Elevated eosinophils following treatment with sipuleucel-T in men with prostate cancer is associated with antigen-specific immune response and prolonged survival. 52nd American Society of Hematology Annual Meeting and Exposition, December 4–7, 2010, Orlando, FL
  • 12
    Sims RB, Wener MH, dela Rosa CP et al. Increased gamma globulin following immunotherapy with sipuleucel-T is associated with antigen-specific antibody responses. 52nd American Society of Hematology Annual Meeting and Exposition, December 4–7, 2010, Orlando, FL
  • 13
    Sheikh NA, Wesley JD, Chadwick E et al. Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T. J Clin Oncol 2011; 29 (Suppl. 7): (abstr 155)
  • 14
    Stewart FP, Dela Rosa CP, Sheik NA et al. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. J Clin Oncol 2010; 28: 4552
  • 15
    Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005; 4: 5560
  • 16
    Beer TM, Bernstein GT, Corman JM et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol 2007; 25: 5059
  • 17
    Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107: 6774
  • 18
    Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010; 70: 9831000
  • 19
    Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011; 8: 55161
  • 20
    Di Lorenzo G, Buonerba C. Kidney cancer: overall survival is an unsuitable primary end point. Nat Rev Urol 2010; 7: 3678
  • 21
    Medicare to cover Dendreon's prostate drug. 30 June 2011. Reuters. Available at: http://www.reuters.com/article/2011/06/30/dendreon-provenge-idUSN1E75T1LH20110630. Accessed November 2011